Brought to you by 
Millenium Biologix gets rights to Allelix's BCSF
13 Jul 1999
Executive Summary
Canadian biotechnology company Millenium Biologix has acquired worldwide development and marketing rights to Allelix's (CNS, hormone, and gene-related diseases) novel bone cell stimulating factor (BCSF) for use in medical devices and implants.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Medical Devices
- Implantable Devices
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Millenium Biologix gets rights to Allelix's BCSF
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice